Phycoerythrin is emerging as a high-value algae-derived product with important applications in life sciences and medical research. Naturally produced by red algae and cyanobacteria, this red fluorescent phycobiliprotein helps organisms capture light in deep or low-light marine environments.
Its strong fluorescent properties have made phycoerythrin an important tool in biomedical applications, particularly in techniques that require precise detection and visualisation. It is widely used in flow cytometry, immunofluorescence, biomedical imaging and diagnostic research, where its brightness, purity and spectral performance offer significant advantages.
The growing interest in phycoerythrin reflects the broader potential of algae as a source of advanced natural compounds. Beyond their role in food, feed, cosmetics and sustainability-focused materials, algae are increasingly being explored for high-value applications in biotechnology and medicine.
Market estimates suggest that the phycoerythrin sector remains relatively small but is expected to grow in the coming years. Some projections value the market at around USD 3.4 million in 2025, with expected growth to USD 5 million by 2032. Other sources place the market at a significantly higher level, between USD 60 million and USD 66 million over the 2023–2031 period.
The variation between estimates highlights a key challenge for the sector: the market remains fragmented and poorly standardised. Differences in purity levels, extraction methods, applications and commercial definitions can make it difficult to compare data across sources.
Even so, phycoerythrin’s role in research and diagnostics positions it as one of the most promising examples of how algae-based compounds can support innovation in modern medicine. As demand for advanced biological tools grows, algae may continue to provide new solutions for imaging, detection and biomedical analysis.
